PharmaNet Development Group’s subsidiary, PharmaNet Canada, Inc. and Maisonneuve-Rosemont Hospital (HMR) and its Research Center, have agreed to collaborate in the conduct of pharmacokinetic studies in patients with impaired renal function.

PharmaNet’s clinical pharmacology unit in Canada evaluates new drugs in Phase I studies for its clients. Under the current FDA draft guidance, certain studies require the evaluation of drug products in study participants that have impaired renal function. The collaboration with HMR will provide PharmaNet with enhanced access to potential study participants with mild, moderate, or severe impaired renal function.

“We are very pleased to partner with HMR,” said Riaz Bandali, president, Early Stage Development. “Demand for the conduct of pharmacokinetic studies in patients with impaired renal function is increasing. By partnering with HMR, a leading nephrology center and specialized hospital, we can efficiently conduct trials in patients with various levels of renal impairment, while assuring the patients’ safety and well-being.”

“By partnering with PharmaNet, our renal impaired patients have the opportunity to contribute to the evaluation of innovative, potentially life-saving therapeutics in a safe environment with their own physicians,” said Dr. Vincent Pichette, Nephrologist-Pharmacologist and Director of the Nephrology Research, Maisonneuve-Rosemont Hospital.